Related Experiment Video
Updated: Apr 28, 2026

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Identification of an Adamantyl Azaquinolone JNK Selective Inhibitor
Nancy-Ellen Haynes1, Nathan R Scott1, Li C Chen1
1Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
Abstract:
3-[4-((1S,2S,3R,5S,7S)-5-Hydroxyadamantan-2-ylcarbamoyl)benzyl]-4-oxo-1-phenyl-1,4-dihydro-[1,8]naphthyridine-2-carboxylic acid methyl ester (4) was identified as a novel, druglike and selective quinolone pan JNK inhibitor. In this communication, some of the structure-activity relationship of the azaquinolone analogues leading to 4 is discussed. The focus is on how changes at the amide functionality affected the biochemical potency, cellular potency, metabolic properties, and solubility of this class of JNK inhibitors. Optimization of these properties led to the identification of the adamantyl analogue, 4. 4 achieved proof of mechanism in both rat and mouse TNF-α challenge models.
Related Concept Videos
Inhibition of CDK Activity
Inhibition of Cdk Activity
The JAK-STAT Signaling Pathway
Inhibitors of Bacterial Protein Synthesis
cAMP-dependent Protein Kinase Pathways
MAPK Signaling Cascades

